The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Eliseeva D.D.

Research Center of Neurology

Vasilyev A.V.

Central Research Institute of Dentistry and Maxillofacial Surgery;
Research Centre for Medical Genetics

Abramova A.A.

Research Center of Neurology

Kochergin I.A.

Research Center of Neurology

Zakharova M.N.

Research Center of Neurology

Monoclonal antibody therapies for rapidly progressive and highly active multiple sclerosis in the era of the COVID-19 pandemic

Authors:

Eliseeva D.D., Vasilyev A.V., Abramova A.A., Kochergin I.A., Zakharova M.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2): 31‑36

DOI: 10.17116/jnevro202112107231

Read: 4209 times

Download PDF (RU)
Contact the author
Table of contents

MONOCLONAL ANTIBODY THERAPIES FOR RAPIDLY PROGRESSIVE AND HIGHLY ACTIVE MULTIPLE SCLEROSIS IN THE ERA OF THE COVID-19 PANDEMIC
MONOCLONAL ANTIBODY THERAPIES FOR RAPIDLY PROGRESSIVE AND HIGHLY ACTIVE MULTIPLE SCLEROSIS IN THE ERA OF THE COVID-19 PANDEMIC

To cite this article:

Eliseeva DD, Vasilyev AV, Abramova AA, Kochergin IA, Zakharova MN. Monoclonal antibody therapies for rapidly progressive and highly active multiple sclerosis in the era of the COVID-19 pandemic. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2):31‑36. (In Russ.)
https://doi.org/10.17116/jnevro202112107231

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Autoimmune hepa­titis: pitfalls of diagnosis and therapy (clinical case). Russian Journal of Evidence-Based Gastroenterology. 2024;(4):95-103
Loca­lization features of FAP-positive acti­vated stro­mal cells in fibrosis in patients with new coro­navirus infe­ction COVID-19. Russian Journal of Archive of Pathology. 2024;(6):5-14
The role of drug Cyto­flavin in the correction of dysautonomia in patients with post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):140-146
Lapa­roscopic appe­ndectomy for appe­ndiceal muco­cele in a patient with COVID-19. Endo­scopic Surgery. 2024;(6):41-45
Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data). Russian Journal of Preventive Medi­cine. 2024;(12):114-121
Sele­ctive anosmia for mono­molecular odorants in a cohort of young indi­viduals. Russian Rhinology. 2024;(4):262-268
The resu­lts of the examination of patients with chro­nic gene­ralized periodontitis after novel coro­navirus infe­ction. Russian Journal of Stomatology. 2024;(4):18-22
Waiting for Disease X: a plan for preparing Russian labo­ratory services for the next pandemic. Labo­ratory Service. 2024;(4):5-11
Diffuse changes in the brain in the acute phase of COVID-19 and after infe­ction. Russian Journal of Archive of Pathology. 2025;(1):5-15
Liver pathology in COVID-19. Russian Journal of Archive of Pathology. 2025;(1):53-59
Abstract:

As the COVID-19 pandemic continues, reducing the risk of infection for immunocompromised patients remains an important issue. Patients with aggressive multiple sclerosis (MS) require immunosuppressive therapy in order to control the overactive autoimmune response. Preliminary international and national trials demonstrate that older age, higher disability status and progressive MS are generally associated with a more severe clinical course of COVID-19. However, uncertainty remains about the effect of disease-modifying therapies on the COVID-19 clinical presentation. In this article, we pay special attention to monoclonal antibodies used for immune reconstitution therapy, which results in significant changes to the T-cell and/or B-cell repertoire. Based on the published data from registries in different countries, we attempted to estimate the benefits and risks of these therapies in a complicated epidemiological setting.

Keywords:

highly active multiple sclerosis
immunosuppressive therapy
COVID-19
natalizumab
alemtuzumab
ocrelizumab

Authors:

Eliseeva D.D.

Research Center of Neurology

Vasilyev A.V.

Central Research Institute of Dentistry and Maxillofacial Surgery;
Research Centre for Medical Genetics

Abramova A.A.

Research Center of Neurology

Kochergin I.A.

Research Center of Neurology

Zakharova M.N.

Research Center of Neurology

Received:

16.04.2021

Accepted:

16.04.2021

Close metadata

References:

  1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. Longo DL, ed. N Engl J Med. 2018;378(2):169-180.  https://doi.org/10.1056/NEJMra1401483
  2. Zaharova MN. Monoklonal’nye antitela v nevrologii: realii i perspektivy. Annaly klinicheskoj i eksperimental’noj nevrologii. 2018;4:34-38. (In Russ.).
  3. Daz C, Zarco L, Rivera DM. Highly Active Multiple Sclerosis: An update. Multiple Sclerosis and Related Disorders. 2019;30:215-224.  https://doi.org/10.1016/j.msard.2019.01.039
  4. Freedman M, Rush C. Severe, Highly Active, or Aggressive Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology. 2016;22:761-784.  https://doi.org/10.1212/con.0000000000000331
  5. Ruggieri S, Pontecorvo S, Tortorella C, Gasperini C. Induction treatment strategy in multiple sclerosis: a review of past experience and future perspectives. Multiple Sclerosis and Demyelinating Disorders. 2018;3:5-9.  https://doi.org/10.1186/s40893-018-0037-7
  6. Giovannoni G, Hawkes C, Lechner-Scott J, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020;39:102073. https://doi.org/10.1016/j.msard.2020.102170
  7. https://www.ructrims.org/files/2020/%D0%A0%D0%A1_%D0%B8_COVID-19_%D0%A0%D0%B5%D0%BA%D0%BE%D0%BC%D0%B5%D0%BD%D0%B4%D0%B0%D1%86%D0%B8%D0%B8_%D0%92%D0%9E%D0%9D.pdf
  8. Niino M. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006;59:748-754.  https://doi.org/10.1002/ana.20859
  9. Luna G. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77:184-191.  https://doi.org/10.1001/jamaneurol.2019.3365
  10. Polman CH, O’Connor PW, Havrdova E. Investigators A. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.  https://doi.org/10.1056/NEJMoa044397
  11. Butzkueven H. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatr. 2020;91:660-668.  https://doi.org/10.1136/jnnp-2019-322326
  12. Schwab N, Schneider-Hohendorf T, Melzer N, et al. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology. 2017;88:1197-1205. https://doi.org/10.1212/WNL.0000000000003739
  13. Prosperini L. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;4:23-29.  https://doi.org/10.1177/1756286419837809
  14. Louapre C, Collongues N, Stankoff B, et al. Patients with MS treated with immunosuppressive agents: across the COVID-19 spectrum. Rev Neurol. 2020;176:523-525.  https://doi.org/10.1016/j.neurol.2020.04.009
  15. Borriello G, Ianniello A. COVID-19 occurring during natalizumab treatment: a case report in a patient with extended interval dosing approach. Mult Scler Relat Disord. 2020;41:102165. https://doi.org/10.1016/j.msard.2020.102165
  16. Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92(7):699-702.  https://doi.org/10.1002/jmv.25915
  17. Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antivir Res. 2020;177:104759. https://doi.org/10.1016/j.antiviral.2020.104759
  18. Plavina T, Muralidharan KK, Kuesters G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurol. 2017;89(15):1584-1593. https://doi.org/10.1212/WNL.0000000000004485
  19. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: Immunopathology in COVID-19. Neurol. 2020;12:34-38.  https://doi.org/10.1002/art.41285
  20. Sormani MP. Italian study group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020;19:481-482.  https://doi.org/10.1016/S1474-4422(20)30147-2
  21. Pfeuffer S, Schmidt R, Straeten FA, et al. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. J Neurol. 2019;266(1):165-173.  https://doi.org/10.1007/s00415-018-9117-z
  22. Malucchi S, Capobianco M, Lo Re M, et al. High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. Neurol Ther. 2017;6(1):145-152.  https://doi.org/10.1007/s40120-016-0058-0
  23. Fernández Ó. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Mult Scler Relat Disord. 2017;17:75-83.  https://doi.org/10.1016/j.msard.2017.07.003
  24. Brownlee W, Bourdette D, Broadley S, et al. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020;94(22):949-952.  https://doi.org/10.1212/WNL.0000000000009507
  25. Wray S, Havrdova E, Snydman DR, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019;25(12):1605-1617. https://doi.org/10.1177/1352458518796675
  26. Möhn N, Konen FF, Pul R, et al. Experience in Multiple Sclerosis Patients with COVID-19 and Disease Modifying Therapies: A Review of 873 Published Cases. J Clin Med. 2020 Dec 16;9(12):4067. https://doi.org/10.3390/jcm9124067
  27. Matías-Guiu J, Montero-Escribano P, Pytel V, et al. Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Mult Scler Relat Disord. 2020;44:102297. https://doi.org/10.1016/j.msard.2020.102297
  28. Fernández-Díaz E, Gracia-Gil J, García-García JG, et al. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab. Mult Scler Relat Disord. 2020;45:102402. https://doi.org/10.1016/j.msard.2020.102402
  29. Carandini T, Pietroboni AM, Sacchi L, et al. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression. Mult Scler. 2020;26(10):1268-1269. https://doi.org/10.1177/1352458520926459
  30. Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21:22-34.  https://doi.org/10.1177/1352458514549398
  31. Li Z, Richards S, Surks HK, et al. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol. 2018;194:295-314.  https://doi.org/10.1111/cei.13208
  32. Celsi F, Galleguillos L. COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID. Mult Scler Relat Disord. 2020;46:102447. https://doi.org/10.1016/j.msard.2020.102447
  33. Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017;7:56-60.  https://doi.org/10.1001/jamaneurol.2017.0676
  34. McCarthy CL, Tuohy O, Compston DA, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872-876.  https://doi.org/10.1212/WNL.0b013e3182a35215
  35. Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflammation. 2017;4(4):360-365.  https://doi.org/10.1212/NXI.0000000000000360
  36. Rolla S, Maglione A, De Mercanti SF, Clerico M. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis. Cells. 2020;9(6):1396-1399. https://doi.org/10.3390/cells9061396
  37. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234.  https://doi.org/10.1056/NEJMoa1601277
  38. Novi G, Mikulska M, Briano F, et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord. 2020;42:102120. https://doi.org/10.1016/j.msard.2020.102120
  39. Bar-Or A, Calkwood JC, Chognot C, et al. Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis D (VELOCE phase III trial). Neurology. 2020;95(14):e1999-e2008. https://doi.org/10.1212/WNL.0000000000010380
  40. Korsukewitz C, Reddel SW, Bar-Or A, Wiendl H. Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature. Nat Rev Neurol. 2020;16(9):493-505.  https://doi.org/10.1038/s41582-020-0385-8
  41. Owji H, Negahdaripour M, Hajighahramani N. Immunotherapeutic approaches to curtail COVID-19. Int Immunopharmacol. 2020;88:106924. https://doi.org/10.1016/j.intimp.2020.106924
  42. Peeters LM, Parciak T, Walton C, et al. COVID-19 in people with multiple sclerosis: A global data sharing initiative. Mult Scler. 2020;26(10):1157-1162. https://doi.org/10.1177/1352458520941485
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.